Risen Pharma Initiates Phase 2 Trial of RP902 for Alzheimer's Disease in China
Key Insights
Risen Pharma (search) has launched a Phase 2 clinical trial in China evaluating RP902, an oral small-molecule drug for mild cognitive impairment (search) due to Alzheimer's disease (search).
The multicenter, randomized, double-blind, placebo-controlled study targets ApoE ε4 carriers and uses the Clinical Dementia Rating Scale-Sum of Boxes as its primary endpoint.
RP902 demonstrated significant inhibition of neurotoxic Aβ oligomers (search) and cognitive function improvement in preclinical studies, with favorable safety in Phase 1 trials.
Risen Pharma (search), a clinical-stage biotech company, has initiated a Phase 2 clinical trial in China for RP902, an oral small-molecule drug targeting mild cognitive impairment (search) (MCI) due to Alzheimer's disease (search). The announcement comes as China faces a significant disease burden, with Alzheimer's disease affecting 6.0% of people aged 65 and above, representing approximately 1 in every 17 individuals.
Trial Design and Objectives
The Phase 2 study is designed as a multicenter, randomized, double-blind, placebo-controlled trial to evaluate both safety and efficacy of RP902 in treating mild cognitive impairment (search) due to Alzheimer's disease (search). The primary endpoint focuses on the change from baseline in the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) score, a validated assessment tool for cognitive and functional decline.
The clinical trial is co-led by Professor Yi Tang from Xuanwu Hospital (search) affiliated to Capital Medical University (search) and Professor Yongjun Wang from Beijing Tiantan Hospital (search) affiliated to Capital Medical University. The study has been registered under the identifier NCT07579884.
Targeted Patient Population
RP902 specifically targets patients with mild cognitive impairment (search) due to Alzheimer's disease (search) who are apolipoprotein E ε4 (search) (ApoE ε4) carriers. This genetic subgroup represents a particularly vulnerable population, as ApoE ε4 carriers typically experience earlier disease onset and faster progression compared to non-carriers. Currently, limited treatment options are available for this patient subset.
Preclinical and Early Clinical Data
Preclinical studies of RP902 have demonstrated significant inhibition of neurotoxic Aβ oligomers (search) and improvements in cognitive function. The drug has successfully completed Phase 1 clinical trials, showing favorable safety and tolerability profiles. These results supported the advancement to the current Phase 2 study.
Therapeutic Potential and Differentiation
RP902 has the potential to become a first-in-class disease-modifying therapy for Alzheimer's disease (search). Compared with existing therapies, the drug offers several potential advantages including the ability to delay disease progression, a favorable safety profile, and the convenience of oral administration. This combination of features positions RP902 as a differentiated treatment option specifically for Alzheimer's disease patients carrying the ApoE ε4 allele.
Company Background
Risen Pharma (search) operates as an internationally competitive clinical-stage biotech company with integrated capabilities spanning all stages of drug development, from lead identification and optimization through preclinical evaluation, clinical development, and commercialization. The company specializes in neurodegenerative diseases like Alzheimer's, utilizing small molecules, PROTACs, and siRNA technologies to develop a comprehensive therapeutic platform. Based on strong in-house R&D capabilities, Risen has advanced over 20 innovative drug candidates and built a differentiated pipeline across degenerative and metabolic diseases, autoimmune diseases, cancers, and infectious diseases.